A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2012

At a glance

  • Drugs PF 4958242 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 07 May 2012 Actual patient number 30 added as reported by ClinicalTrials.gov.
    • 07 May 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
    • 07 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top